A thiazolyl-containing propenone derivative and its application in the preparation of kinase inhibitors
By optimizing the 2-propenone skeleton and introducing thiazolyl, a new acrylonitrile kinase inhibitor was developed, which solved the problem of high cost and low success rate of existing anti-cancer drugs, and achieved effective inhibition of protein kinase CK2. It has a strong anti-cancer drug effect.
Patent Information
- Application Number
- CN202110754618.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-07-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-07-02
AI Technical Summary
The development cost of existing anti-cancer drugs is high and the success rate is low, making it difficult to effectively inhibit the overactivity of protein kinase CK2, leading to the challenges of malignant tumors and neurodegenerative diseases.
By optimizing the 2-propenone skeleton, introducing thiazolyl groups, a novel acrylate kinase inhibitor was synthesized, and using its inhibitory activity on protein kinase CK2, a compound with strong anti-cancer efficacy was developed.
Effective inhibition of protein kinase CK2 was achieved, and strong anti-cancer efficacy was demonstrated. The IC50 values were 142.8μM and 100.1μM, respectively, which had important clinical application prospects.
Smart Images

Figure CN113603657B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to a thiazolyl-containing propenone derivative, a preparation method thereof and an application thereof as a kinase inhibitor. Background Art
[0002] Cancer is the number one killer threatening human health and life. Its incidence has been increasing year by year in recent years. The development of anticancer drugs has become a very challenging and significant research topic in life sciences and medicinal chemistry due to its high cost and low success rate.
[0003] Protein kinase CK2 participates in regulating the physiological processes of cells by participating in multiple signaling pathways such as NF-κB, Wnt and P13'K in a cascade and vertical manner. However, when its regulation in the body is out of control, it will cause serious diseases such as malignant tumors and neurodegenerative diseases. The development of anticancer drugs targeting it has important clinical value and application prospects.
[0004] Isoliquiritigenin compounds containing acrylone skeleton are widely distributed in some medicinal plants and synthetic active molecules, showing a wide range of biological activities and becoming an important source of anticancer lead compounds. Based on the research of domestic and foreign literature, patents and the previous research work of the research group, the present invention optimizes the combination of anticancer drug efficacy fragment thiazole group for 2-propenone skeleton, and then obtains a new type of propenone kinase inhibitor. Summary of the invention
[0005] The invention relates to a thiazolyl-containing propenone derivative, a preparation method thereof and application thereof as a kinase inhibitor.
[0006] The inventors conducted an in-depth comparative analysis of the differences in the binding modes of the natural product isoliquiritigenin and the curcumin derivative ferulic acid methyl with CK2, identified the overlap of the aromatic ring and the straight-chain skeleton of the two, and demonstrated that the propenone skeleton as a new straight-chain lead skeleton has the potential for in-depth research, which shows that the combination optimization of the anticancer drug fragments targeting the 2-propenone skeleton of isoliquiritigenin is highly reasonable and feasible. By optimizing the anticancer drug groups with different structures and properties, it is finally proposed that the R 1 A thiazolyl group was introduced into the phosphodiesterase to obtain a novel compound with anti-protein kinase CK2 activity.
[0007] In order to achieve the purpose of the present invention, the present invention provides a thiazolyl-containing propenone derivative having a compound shown in the general formula (I):
[0008]
[0009] Among them, R 1 for Any one of .
[0010] When R 1 for When the compound is 3-((E)-2-((thiazol-2-yl)carbamoyl)vinyl)phenol (Compound 1)
[0011] When R 1 for When the compound is 3-((E)-2-((1,3,4-thiadiazol-2-yl)carbamoyl)vinyl)phenol (Compound 2).
[0012]
[0013] The present invention also provides a method for preparing the above two thiazolyl-containing propenone derivatives, and the reaction process of the method is:
[0014]
[0015] R 1 for Any one of .
[0016] The specific synthesis steps of the compound provided by the present invention are as follows:
[0017] (1) Compound C was dissolved in THF, and then the mixed solution was slowly added dropwise to the mixture containing Compound R under ice bath conditions. 1 -NH2, triethylamine, THF in a mixed system, stirred for 1-2h, concentrated in vacuo to obtain a crude product, the crude product was separated and purified by silica gel column chromatography, and dried in vacuo to obtain compound d;
[0018] (2) Compound d obtained in step (1) is dissolved in methanol, and an aqueous solution of NaOH is added, stirred, concentrated in vacuo, acidified with dilute hydrochloric acid to a pH of 4-6, filtered with water, and dried to obtain compound e, i.e., a thiazolyl-containing propenone derivative.
[0019] In the above method:
[0020] In the step (1):
[0021] The compound c, R 1 —NH 2 The molar ratio of triethylamine is 1-2:1:2-4;
[0022] Add the mixed solution of compound c and THF to compound R 1 -NH 2 , triethylamine and THF are used as the reaction system, and the reaction temperature during stirring is 25-30°C;
[0023] The eluents used for silica gel column chromatography are methanol and dichloromethane, and gradient elution is adopted, with a volume ratio of dichloromethane to methanol of 20:1-60:1.
[0024] In the step (2):
[0025] The molar ratio of the compound d to NaOH is 1:1-2;
[0026] The reaction time is controlled within 1h-3h;
[0027] The reaction temperature is 25-30°C;
[0028] The concentration of the hydrochloric acid solution used for hydrochloric acid acidification is 10%-30%, and the pH of the solution is controlled to be 4-6.
[0029] The use of the thiazolyl-containing propenone derivatives described in the present invention in the preparation of kinase inhibitors falls within the protection scope of the present invention.
[0030] Furthermore, the thiazolyl-containing propenone derivatives of the present invention have protein kinase CK2α inhibitory activity. DETAILED DESCRIPTION
[0031] The present invention is further described below in conjunction with embodiments, but the present invention is not limited to the following embodiments.
[0032] The structural formulas of Compound 1 and Compound 2 involved in the following examples are as follows:
[0033]
[0034]
[0035] The reaction steps of the synthesis are as follows (including the synthesis steps from compound a to compound c):
[0036]
[0037] R 1 for Any one of .
[0038] Example 1 Synthesis of 3-(3-(2-aminothiazole)propenyl)phenol (Compound 1)
[0039] (1) Synthesis of 3-(3-acetoxyphenyl)-2-propenoic acid
[0040] Dissolve m-hydroxyphenyl acrylic acid a (1.0 g, 6.09 mmol) in pyridine (10 ml), place the mixture in an ice bath, add acetic anhydride (0.86 ml, 9.14 mmol), remove the ice bath, react overnight, adjust the pH value to 5-6 by adding hydrochloric acid, a precipitate is generated, filtered, washed with water, the solvent is removed in vacuo, and dried to obtain 1.2 g of a white solid represented by structural formula b, with a yield of 95%.
[0041] (2) Synthesis of (2E)-3-[3-(acetyloxy)phenyl]-2-acryloyl chloride
[0042] Compound b (0.3 g, 1.45 mmol) was dissolved in THF, and the mixture was placed in an ice bath. A mixed solution of oxalyl chloride (0.38 ml, 4.37 mmol) and THF was slowly added dropwise, and 2-3 drops of DMF were added for catalysis. The ice bath was removed, and the reaction was carried out at room temperature overnight. The mixture was concentrated in vacuo to obtain 0.29 g of a white solid represented by structural formula c, with a yield of 89%.
[0043] (3) Synthesis of 3-(3-(2-aminothiazole)propenyl)acetate
[0044] Compound c (0.58 g, 2.60 mmol) was dissolved in THF, and then the mixed solution was slowly added dropwise to a mixed system consisting of compound 2-aminothiazole (0.2 g, 1.94 mmol), triethylamine (0.54 ml, 3.88 mmol), and THF under ice bath conditions, stirred for 1-2 hours, and concentrated in vacuo to obtain a crude product, which was separated and purified by silica gel column chromatography, with dichloromethane and methanol as eluents, and gradient elution, with a volume ratio of dichloromethane to methanol of 20:1-60:1. Vacuum drying gave 0.73 g of a white solid represented by structural formula d, with a yield of 86%.
[0045] (4) Synthesis of 3-(3-(2-aminothiazole)propenyl)phenol
[0046] 3-(3-(2-aminothiazole)propenyl)acetate d (0.4 g, 1.38 mmol) was dissolved in methanol (8 mL), and an aqueous solution (8 mL) of NaOH (0.108 g, 2.7 mmol) was added and stirred. The mixture was concentrated in vacuo, acidified with dilute hydrochloric acid to a pH of 4-6, filtered with water, and dried to obtain 0.62 g of the target product, compound 1, as a white solid, with a yield of 71%. 1HNMR(400MHz,DMSO-d6)δ12.36(s,1H),9.76(s,1H),7.62(d,J=15.8Hz,1H),7.51(d,J =3.5Hz,1H),7.25(dd,J=5.6,2.1Hz,2H),7.07–7.01(m,2H),6.87–6.82(m,2H).ESI-MS m / z:245.0386[MH] - C 12 H 10 N 2 O 2 S,calcd for C 12 H 10 N 2 O 2 S:246.0463.
[0047] Example 2 Synthesis of 3-(3-(2-amino-1,3,4-thiadiazole)propenyl)phenol (Compound 2)
[0048] (1) Synthesis of 3-(3-acetoxyphenyl)-2-propenoic acid
[0049] Dissolve m-hydroxyphenyl acrylic acid a (1.0 g, 6.09 mmol) in pyridine (10 ml), place the mixture in an ice bath, add acetic anhydride (0.86 ml, 9.14 mmol), remove the ice bath, react overnight, adjust the pH value to acidic (5-6) by adding hydrochloric acid, a precipitate is generated, filtered, washed with water, the solvent is removed in vacuo, and dried to obtain 1.2 g of a white solid represented by structural formula b, with a yield of 95%.
[0050] (2) Synthesis of (2E)-3-[3-(acetyloxy)phenyl]-2-acryloyl chloride
[0051] Compound b (0.3 g, 1.45 mmol) was dissolved in THF, and the mixture was placed in an ice bath. A mixed solution of oxalyl chloride (0.38 ml, 4.37 mmol) and THF was slowly added dropwise, and 2-3 drops of DMF were added for catalysis. The ice bath was removed, and the reaction was carried out at room temperature overnight. The mixture was concentrated in vacuo to obtain 0.29 g of a white solid represented by structural formula c, with a yield of 89%.
[0052] (3) Synthesis of 3-(3-(2-amino-1,3,4-thiadiazole)propenyl)acetate
[0053] Compound c (0.29 g, 1.30 mmol) was dissolved in THF, and then the mixed solution was slowly added dropwise to a mixed system consisting of compound 2-amino-1,3,4-thiadiazole (0.1 g, 0.97 mmol), triethylamine (0.27 ml, 1.94 mmol), and THF under ice bath conditions, stirred for 1-2 hours, and concentrated in vacuo to obtain a crude product, which was separated and purified by silica gel column chromatography, with dichloromethane and methanol as eluents, and gradient elution was used, with a volume ratio of dichloromethane to methanol of 20:1-60:1. Vacuum drying gave 0.31 g of a white solid represented by structural formula d, with a yield of 82%.
[0054] (4) Synthesis of 3-(3-(2-amino-1,3,4-thiadiazole)propenyl)phenol
[0055] 3-(3-(2-aminothiazole)propenyl)acetate d (0.2 g, 0.69 mmol) was dissolved in methanol (4 mL), and an aqueous solution (4 mL) of NaOH (0.054 g, 1.35 mmol) was added and stirred. The mixture was concentrated in vacuo, acidified with dilute hydrochloric acid to a pH of 4-6, filtered with water, and dried to obtain 0.25 g of the target product, compound 1, as a white solid, with a yield of 64%. 1 HNMR(400MHz,DMSO-d6)δ8.89(s,1H),8.50(s,1H),7.66(d,J=15.8Hz,1H),7.19(d,J =7.7Hz,2H),6.80(dd,J=17.4,11.5Hz,2H),6.60(dd,J=9.7,5.2Hz,1H).ESI-MS[MH] - m / z:246.0344,calcd forC 11 H 9 N 3 O 2 S: 247.0415. Example 3 ADP-Glo kinase activity assay was used to determine the inhibitory activity of compound 1 and compound 2 on protein kinase CK2
[0056] In a 96-well plate with a white bottom, 5 μL of the test compound (inhibitor) of different concentrations, 10 μL of protein kinase CK2 solution and 10 μL of substrate / ATP mixed solution were added in sequence to obtain a total volume of 25 μL of reactants. The reaction was started by adding the substrate / ATP to the kinase and incubated at room temperature for 60 minutes. Subsequently, 25 μL of ADP-Glo reagent was added to each reaction well to stop the reaction and consume the remaining ATP in each well, and incubated at room temperature for 40 minutes. Finally, 50 μL of kinase detection reagent was added to each well and incubated at room temperature for 30 minutes. The generated ADP was converted into ATP and reacted with the luciferase in the detection reagent to emit light, and then the luminescence value was detected using an enzyme reader. The inhibitory effect of different compounds on protein kinase CK2 at different concentrations was calculated by comparing with 100% inhibition of the reaction mixture without enzyme (negative control) and 0% inhibition of the reaction mixture with 5% DMSO (positive control). As can be seen from Table 1, the IC of compound 1 inhibiting the activity of CK2α 50 The value was 142.8 μM, and the IC of compound 2 for inhibiting CK2α activity was 50 The value is 100.1 μM.
[0057] Table 1 Inhibitory activity of compound 1 and compound 2 on protein kinase CK2 (μM)
[0058]
Claims
1. A method for preparing a thiazolyl-containing propenone derivative, characterized in that: The following steps are involved: (1) Compound c was dissolved in tetrahydrofuran (THF), and the mixed solution was then slowly added dropwise to a mixed system consisting of compound R1-NH2, triethylamine, and THF under ice bath conditions, stirred for 1-2 hours, and concentrated in vacuo to obtain a crude product. The crude product was separated and purified by silica gel column chromatography, and dried in vacuo to obtain compound d; (2) Dissolve the obtained compound d in methanol, add an aqueous solution of NaOH, and stir; concentrate in vacuo, acidify with dilute hydrochloric acid to a pH of 4-6, add water, filter, and dry to obtain compound e, i.e., a thiazolyl propenone derivative; In step (1), the molar ratio of compound c, R1-NH2 and triethylamine is 1-2:1:2-4; In step (1), the eluents used for the silica gel column chromatography are methanol and dichloromethane, and gradient elution is adopted, and the volume ratio of dichloromethane to methanol is 20:1-60:1; Among them, R1 is Any of the following: In step (1), after adding the mixed solution of compound c and THF to the reaction system consisting of compound R1-NH2, triethylamine and THF, the reaction temperature during stirring is 25-30°C; In step (2), the molar ratio of compound d to NaOH is 1:1-2; In step (2), the reaction time is controlled at 1h-3h; the reaction temperature is 25-30°C; In step (2), the mass percentage concentration of the hydrochloric acid solution used for hydrochloric acid acidification is 10%-30%, and the pH value of the solution is controlled to be 4-6.
Citation Information
Patent Citations
Five-membered azole-containing heterocyclic chalcone derivative, and preparation method and medical use thereof
CN109879808A
N-p-hydroxylphenyl amides with choleretic action
GB828695A
KR20210040643A
